

FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: **Callitas Health Inc. (Callitas)**

Trading Symbol: LILY

Number of Outstanding Listed Securities: **32,462,095**

Date: March 7, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CSE.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Formed in early 2015, Callitas Health Inc, is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a

reformulation of Orlistat and assets from 40J's LLC, the Company distributes ToConceive, a FDA cleared fertility product.

Callitas trades on the Canadian Securities Exchange (CSE) under the ticker symbol "LILY" as well as on the OTC as "MPHMD" and FWB (Frankfurt Stock Exchange) as "T3F3."

Callitas Health is an integrated clinical stage pharmaceutical development corporation with an OTC products division in the fertility care & female/male sexual wellness space. The specific drug product(s) under development are segmented into separate operating LLC's for JV/project specific funding/partnering & operations outside of the parent public company. Currently Callitas wholly owns 100% of the OTC Products Division & CT Development Companies 2, 3 & 4 and 85% of CT Development 1 (inventor & outside investor/angel funding allocated at 15%).

- OTC Products Division- Fertility Care, Female & Male Sexual Wellness, etc (commercialized and pipeline products list and accompanying information available upon request).
 - CT Development 1- Orphan Drug Development for Urea Cycle Disorders- Submitted ODD/RPD Designation Requests to US FDA. Response expected in 60-90 day timeframe from 11/27/17.
 - CT Development 2- C-103 (modified Orlistat drug product for obesity)- Positive pIND Meeting Letter, Development GAP analysis and Drug Commercialization Plan Available.
 - CT Development 3- Extrinsa (topical tadalafil for Female Sexual Arousal Disorder)- Positive pIND Meeting Letter, Development GAP analysis and Drug Commercialization Plan Available.
 - CT Development 4- "Cannamint" (Oral/Buccal arginine/menthol enhanced delivery of CBD/THC)- Product overview available (Not US FDA regulated).
 - Other products and technologies being evaluated (FS).
2. Provide a general overview and discussion of the activities of management. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The core management team for Callitas Health Inc (CEO, CFO & COO) have been focused on expanding the current distribution of OTC products beyond a few markets in Asia and now South America and advancing the OTC products and drug development projects in question 1, above. The team's business strategy to segment and partner with select organizations focusing on weight management, female wellness and orphan drugs; these initiatives can be defined as successful and on target. We have been in ongoing partnering discussions and communications with international pharmaceutical companies for the drug development projects. We have

also been advancing the OTC business through the multi-channel strategy in the US.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None applicable at this time.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None applicable at this time.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

1. **Callitas entered into an advisory, consultancy and media/press/investor relations contract with TraDigital Marketing Services, based in New York, NY.**

2. **The company is in business discussions with a Confidential/Proprietary contract manufacturer, with a development agreement under negotiations for the development of the Cannamint strip technology. We expect to execute this agreement in March and begin development immediately.**

3. **The company executed a services contract with Liquid Brand Builders for regulatory support and product registration services for Company's OTC products in Canada, product registration(s) will begin in March.**

4. **The company entered into a co-marketing and supply/distribution contract with NFI, the makers/marketers of e.p.t. pregnancy tests for the ToConceive product.**

None of the above are related persons.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None at this time

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets

acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

No additional business relationships have been signed at this time.

8. Describe the acquisition of new customers or loss of customers.

Company entered into a co-marketing & supply/distribution agreement with NFI for retail kits containing the ToConceive product- disclosed above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Callitas received notice of allowance for patent application 15/353,130 on Feb 28, 2018.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None at this time.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Callitas Health has been served with a statement of claim from UTI relating to alleged defaults by one of its subsidiaries in respect to a license agreement covering the Trimtec technology before it was terminated by UTI. UTI is claiming approximately \$200,000. Callitas Health was never a party to this license and does not have any liability thereunder.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No indebtedness occurred during this period.

14. Provide details of any securities issued and options or warrants granted.

None at this time.

15. Provide details of any loans to or by Related Persons.

There were no loans made to or by related parties or persons during this period.

Provide details of any changes in directors, officers or committee members.

None at this time.

16. Discuss any trends that are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None applicable during this period.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: March 7, 2018

James Thompson CEO

James Thompson
Signature

Interim President and CEO
Official Capacity

<i>Issuer Details</i> Name of Issuer Callitas Health Inc.	For Month End February, 2018	Date of Report March 7, 2018
Issuer Address 734 – 1055 Dunsmuir Street		
City/Province/Postal Code Vancouver, B.C. V7X 1B1	Issuer Fax No.	Issuer Fax No.
Contact Name James M Thompson	Contact Position President & CEO	Contact Telephone No. 1-859-868-3131
Contact Email Address info@callitas.com	Web Site Address www.callitas.com	